Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7689660 | 0.83 | KDM4E (0.30) | — | |
| SCHEMBL2272267 | 0.79 | HCAR2 (0.32) | HCAR2 | |
| SCHEMBL6288438 | 0.75 | — | — | |
| SCHEMBL6288649 | 0.68 | TDP1 (0.32) | HCAR2 | |
| SCHEMBL6279742 | 0.68 | HCAR2 (0.32) | HCAR2 | |
| SCHEMBL6279745 | 0.64 | PIN1 (0.31) | — | |
| SCHEMBL15332493 | 0.60 | LMNA (0.34) | HCAR2 | |
| SCHEMBL7146649 | 0.60 | PIN1 (0.47) | HCAR2 | |
| SCHEMBL2804373 | 0.60 | PIN1 (0.44) | HCAR2 | |
| SCHEMBL6287851 | 0.59 | PTGS1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855827-B2 | Compositions for dyeing keratinous fibers comprising pyrazoloazoles; their use in dyeing as oxidation base and dyeing process; and novel pyrazoloazoles | L'ORÉAL (FR) | 2005-02-15 | — | — | US | claimed |
| EP-0923929-B1 | KERATIN FIBRE DYE COMPOSITION CONTAINING PYRAZOLO-AZOLE COMPOUNDS, USE THEREOF AS OXIDATION AGENTS, AND DYEING METHOD; PYRAZOLOAZOLES | OREAL (FR) | 2004-05-12 | — | — | EP | claimed |
| US-20020152558-A1 | Compositions for dyeing keratinous fibers comprising pyrazoloazoles; their use in dyeing as oxidation base and dyeing process; and novel pyrazoloazoles | L'OREAL | 2002-10-24 | — | — | US | claimed |
| US-6379397-B2 | CAPABLE OF GENERATING INTENSE COLORINGS IN VARIED SHADES | L'OREAL S.A. (FR) | 2002-04-30 | — | — | US | claimed |
| US-6855827-B2 | Compositions for dyeing keratinous fibers comprising pyrazoloazoles; their use in dyeing as oxidation base and dyeing process; and novel pyrazoloazoles | L'ORÉAL (FR) | 2005-02-15 | — | — | US | disclosed |
| US-20020152558-A1 | Compositions for dyeing keratinous fibers comprising pyrazoloazoles; their use in dyeing as oxidation base and dyeing process; and novel pyrazoloazoles | L'OREAL | 2002-10-24 | — | — | US | disclosed |
| US-6379397-B2 | CAPABLE OF GENERATING INTENSE COLORINGS IN VARIED SHADES | L'OREAL S.A. (FR) | 2002-04-30 | — | — | US | disclosed |
| US-20020007520-A1 | COMPOSITIONS FOR DYEING KERATINOUS FIBERS COMPRISING PYRAZOLOAZOLES; THEIR USE IN DYEING AS OXIDATION BASE AND DYEING PROCESS; AND NOVEL PYRAZOLOAZOLES | L'OREAL S.A. (FR) | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007520-A1 | COMPOSITIONS FOR DYEING KERATINOUS FIBERS COMPRISING PYRAZOLOAZOLES; THEIR USE IN DYEING AS OXIDATION BASE AND DYEING PROCESS; AND NOVEL PYRAZOLOAZOLES | KRT18, ZYX, TUBB3 | HCAR2 1769/4885 |
| US-20020152558-A1 | Compositions for dyeing keratinous fibers comprising pyrazoloazoles; their use in dyeing as oxidation base and dyeing process; and novel pyrazoloazoles | KRT18, ZYX, TUBB3 | HCAR2 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.